NEWSROOM

Stay current with MiRXES

Featured

Media Releases

Keep up to date with our latest news and activities as we continue to innovate and develop our science and technology, bringing novel products to market. – from Singapore to the world.

Dr Holger Heyn

Dr Holger Heyn, an expert in single-cell genomics and spatial transcriptomics, has joined the Scientific Advisory Board of MiRXES to help advance its development of RNA-powered multi-omics solutions for research and diagnosti

PCR Lab

This new capital will support MiRXES’s growth as a global leader in cancer early detection tests and preventive healthcare

This study shows MiRXES qPCR profiling platform to be superior in reproducibility and detection rate compared to other commercial microRNA profiling platforms when used for validation of blood-based microRNA biomarkers.

A*STAR, TTSH and molecular diagnostic company MiRXES expand range of infectious disease testing solutions with the Fortitude SARS-CoV-2 & Flu A/B Test.

Collaborative study between MiRXES and Janseen shows microRNA-based biomarker signatures may support early identification and diagnosis of

Enhancing activities in Japan not only enable the easier and more accurate diagnosis of gastric cancer which is common case in Japan, but also help to propose the best medical and precision treatment for patients in Japan through their ultra-sensitive microRNA detection.

Media Coverage

Stay informed and keep abreast with our media news.

8 Jul 2021

MiRXES has raised US$77 million in a Series C round, pushing  to commercialise its early cancer detection test kits globally. This latest round values the biotech at over US$500 million and could pave the way for a public listing.

31 Mar 2021

This latest FT ranking of 500 of the region’s high-growth companies is compiled in partnership with Nikkei Asia and research provider Statista. MiRXES is ranked 194 position, and top 30 in Singapore.

Insights

Welcome to our knowledge base of insights in the frontiers of the biotech industry.

Across the many functional teams in MiRXES, from R&D to manufacturing and commercial, our women in science wear many different hats—to great success.

As the world’s first molecular blood test for detecting gastric cancer, GASTROClear could play a pivotal role in stopping the deadly disease in its earliest stages.

Media and Investor Contact

For media enquiries, please email: communications@mirxes.com

Copyright © 2021 MiRXES Pte Ltd. All rights reserved. Terms of Use | Privacy Policy
Scroll to Top